Evidence map›Paper›PMID 27661111›Full record

SynthesisOncotarget2016

Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis.

Jiayuan Wu, Caixia Liang, Manyu Chen, Wenmei Su

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05168527 (An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer), which is not on this map. Cited by 127 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05168527 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer

TypeinterventionalSponsorFudan UniversityRan2021 to 2024Enrolled30ConditionsPancreatic CancerArmsFruquintinib,Albumin Paclitaxel,Gemcitabine
3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiayuan WuNutritional Department, the Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China.
Caixia LiangDepartment of Oncology, the Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China.
Manyu ChenDepartment of Oncology, the Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China.
Wenmei SuDepartment of Oncology, the Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-related stroma plays an active role in tumor invasion and metastasis. The tumor-stroma ratio (TSR) in the pathologic specimen has drawn increasing attention from the field of predicting tumor prognosis. However, the prognostic value of TSR in solid tumors necessitates further elucidation. We conducted a meta-analysis on 14 studies with 4238 patients through a comprehensive electronic search on databases updated on May 2016 to explore the relationship between TSR and prognosis of solid tumors. The overall hazard ratio showed that rich stroma in tumor tissue was associated with poor overall survival (OS) (14 studies, 4238 patients) and disease-free survival (DFS) (9 studies, 2235 patients) of patients with solid tumors. The effect of low TSR on poor OS was observed among various cancer types, but not in the early stage of cervical caner. A significant relationship between low TSR and poor OS was also observed in the subgroup analyses based on study region, blinding status, and Newcastle-Ottawa Scale (NOS) score. Subgroup analyses indicated that cancer type, clinical stage, study region, blinding status, and NOS score did not affect the prognostic value of TSR for DFS. Moreover, low TSR was significantly correlated with the serious clinical stage, advanced depth of invasion, and positive lymph node metastasis. These findings indicate that a high proportion of stroma in cancer tissue is associated with poor clinical outcomes in cancer patients, and TSR may serve as an independent prognostic factor for solid tumors.

Indexed as

Disease-Free SurvivalFemaleHumansLymphatic MetastasisMaleNeoplasmsOdds RatioPrognosisProportional Hazards ModelsQuality ControlRegression AnalysisStromal CellsTreatment OutcomeUterine Cervical Neoplasmsclinicopathological featuresmeta-analysisprognosissolid tumorstumor-stroma ratio

Identifiers

PMID27661111
PMCPMC5356603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.